Acrivon Therapeutics, Inc. (ACRV)
Nasdaq: ACRV · Pharmaceutical Preparations · Watertown, MA · filing with the SEC since 2021
Who owns Acrivon Therapeutics, Inc.
As filed with the SECHolders of 5% or more
2
RA Capital Management, L.P. holds 28.8% of Common Stock, par value $0.001 per share, as its SCHEDULE 13D/A filed Apr 23, 2026 says.
Directors and officers
20
report now, of 22 people on the record since 2022. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
RA Capital Management, L.P.
SCHEDULE 13D/A · filed Apr 23, 2026 · Common Stock, par value $0.001 per share · 21.6% in Mar 23, 2026
Sands Capital Life Sciences Pulse Fund II, L.P.
SCHEDULE 13G/A · filed Aug 13, 2026 · Common Stock, par value $0.001 per share · 6.8% in Aug 13, 2025
Citadel Advisors LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.001 per share (the "Shares") · reported falling below 5%, from 5.5% in Nov 21, 2025
Perceptive Advisors LLC
SCHEDULE 13G/A · filed Jun 4, 2025 · Common Stock, par value $0.001 per share · reported falling below 5%, from 9.9% in May 1, 2025
What ACRV reports owning in othersstakes of 5% or more, and other ties
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 19, 2026.
Insider tradesForm 4
11sales
3purchases
0sales on a scheduled plan
7people selling
$0sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Oct 26, 2025 to Oct 26, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 26, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 31 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Blume-Jensen Peter | President and CEO | 1 | $0 | 0 | 1 | $100,000 |
| Levy Adam D. | Chief Financial Officer | 1 | $0 | 0 | 1 | $0 |
| Devroe Eric | Chief Operating Officer | 1 | $0 | 0 | 1 | $0 |
| Miller Mary | Chief Legal Officer | 4 | $0 | 0 | 0 | $0 |
| Gamelin Erick | Chief Development Officer | 1 | $0 | 0 | 0 | $0 |
| Peterson Katharine | Chief Accounting Officer | 1 | $0 | 0 | 0 | $0 |
| Masson Kristina | EVP - Business Operations | 2 | $0 | 0 | 0 | $0 |